Table 2.
Characteristics of recipients.
| Author | Sample size | Age (years) | Gender | Type of LTx | Indication for LTx | Follow-up | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EVLP | NEVLP | EVLP | NEVLP | EVLP | NEVLP | EVLP | NEVLP | EVLP | NEVLP | ||
| Koch et al. [20] | 11 | 41 | 55±7 | 55±6 | F 13, M 8 | F 17, M 24 | BLT 7, SLT 1, Bilobar 1 | BLT 41 | IPF 2, COPD 8, CPFE 1 | IPF 10, COPD 22, CPFE 3, CF 3, RLTx 1, Sarcoidosis 2 | Up to 500 days |
| Warnecke et al. [16] | 151 | 169 | 50.4± 13.1 | 50.0± 13.6 | F 74, M 77 | F 63, M 106 | BLT 151 | BLT 169 | COPD 46, PF 49, CF 31, IPH 13, Sarcoidosis 4, other 3 | COPD 52, PF 57, CF 40, IPH 6, Sarcoidosis 8, other 6 | Up to 24 months |
| Nilsson et al. [21] | 54 | 271 | 52±12 | 51±13 | NA | NA | BLT 46, SLT 7, Bilobar 1 | BLT 246, SLT 37 | IPF 24, PAH 2, COPD 33, AAD 6, CF 20, other 15 | IPF 25, PAH 6, COPD 28, AAD 13, CF 12, other 16 | Up to 5 years |
| Zhang et al. [22] | 9 | 18 | 53±13.3 | 50±9.5 | F 5, M 4 | F 10, M 8 | BLT 9 | BLT 18 | COPD 6, CF 2, PF 1 | COPD 12, CF 4, PF 2 | Up to 36 months |
| Slama et al. [17] | 35 | 41 | 52.9 (21–68.3) | 54.2 (19.7–66.7) | F 18, M 17 | F 20, M 21 | BLT 35 | BLT 41 | Emphysema 14, PF 9, CF 7, other 5 | Emphysema 21, PF 7, CF 10, other 3 | Up to 90 days |
| Luc et al. [18] | 7 | 4 | 52±18 | 58±4 | F 4, M 3 | F 1, M 3 | NA | NA | IPF 3, emphysema 2, CF 2 | IPF 2, emphysema 1, scleroderma 1 | 1 year |
| Wallinder et al. 2016 [23] | 27 | 145 | 55±13 | 52±14 | NA | NA | BLT 22, SLT 5 | BLT 113, SLT 32 | IPF 22, COPD 33, AAD 7, RLTx 4, CF 19, other 15 | IPF 24, PAH 8, COPD 24, AAD 13, RLTx 9, CF 7, other 15 | Up to 4 years |
| Fisher et al. [24] | 18 | 184 | 56 (20–64) | 51 (18–70) | F 5, M 13 | F 78, M 106 | BLT 16, SLT 2 | BLT 152, SLT 24 | COPD 5, CF 4, ILD 7, NCFB 1, PAH 1 | COPD 40, CF 47, ILD 47, Emphysema 26, NCFB 8, OB 2, PAH 3, other 9 | Up to 12 months |
| Machuca et al. [19] | 28 | 27 | 52±13 | 50±16 | F 12, M 16 | F 12, M 15 | BLT 21, SLT 7 | BLT 21, SLT 6 | IPF 13, emphysema 8, CF 5, RLTx 1, Scleroderma 1 | IPF 12, Emphysema 9, CF 4, RLTx 4, Scleroderma 1 | Up to 7 years |
| Tikkanen et al. [25] | 63 | 340 | 50.3± 14.6 | 52.3± 14.2 | F 32, M 31 | F 141, M 199 | BLT 48, SLT 15 | BLT 295, SLT 45 | PF 22, COPD 20, CF 14, PAH 3, RLTx 1, other 3 | PF 121, COPD 90, CF 67, PAH 14, RLTx 14, other 34 | Up to 5 years |
| Fildes et al. [26] | 9 | 46 | 3±9.4 | 49±12.0 | F 4, M 5 | F 24, M 222 | NA | NA | COPD 6, CF 1, PAH 1, IPF 1 | COPD 24, Bronchiectasis 7, CF 9, PAH 3, IPF 3 | Up to 12 months |
| Sanchez et al. [15] | 42 | 42 | NA | NA | NA | NA | NA | NA | IPF 19, COPD 13, PPH 1, other 9 | IPF 13, COPD 15, PPH 3, other 11 | Up to 1 year |
| Sage et al. [29] | 31 | 81 | 40 (21–60) | 41 (17–65) | F 20, M 11 | F 42, M 39 | BLT 31 | BLT 81 | CF 15, COPD 9, PF 3, other 4 | CF 40, COPD 16, PF 12, other 13 | Up to 1 year |
| Boffini et al. [28] | 8 | 28 | 46.6±9.8 | 51.7±14.7 | F 2, M 6 | F 7, M 21 | BLT 8 | BLT 16, SLT 12 | PF 4 | PF 13 | 30 days |
| Valenza et al. [4] | 7 | 28 | 38±15 | 49±14 | NA | NA | BLT 6, SLT 1 | BLT 14, SLT 14 | CF 4, other 3 | CF 14, PF 11, other 7 | Up to 800 days |
| Wallinder et al. 2014 [29] | 11 | 47 | 56 (19–61) | 56 (21–70) | NA | NA | BLT 8, SLT 3 | BLT 33, SLT 14 | PF 5, COPD 4, other 2 | PF 14, PAH 2, COPD 13, AAD 6, RLTx 5, other 7 | 3 months |
| Cypel et al. [30] | 50 | 253 | Median 56 | Median 56 | NA | NA | BLT 38, SLT 12 | BLT 223, SLT 30 | Emphysema 19, PF 14, CF 12, other 5 | PF or PAH 98 | Up to 3.5 years |
| Zych et al. [31] | 6 | 86 | 43.5± 15.1 | NA | F 2, M 4 | NA | NA | NA | CF 2, Emphysema 3, HSP 1 | NA | Median 297.5 days |
| Aigner et al. [32] | 9 | 119 | 58 (18–66) | 46 (13–66) | F 3, M 6 | F 61, M 58 | BLT 9 | NA | IPF 4, COPD 3, CF 2 | NA | Up to 16 months |
| Lindstedt et al. [33] | 6 | 15 | 54.5 (35–64) | 41 (24–66) | F 3, M 3 | F 9, M 6 | BLT 6 | BLT 15 | COPD 3, PF 1, CF 1, AAD 1 | COPD 5, CF 7, PF 1, emphysema 1, PAH 1 | NA |
Data are presented as n/N, mean±SD, median (range). LTx – lung transplantation; EVLP – ex vivo lung perfusion; NEVLP – non-EVLP; F – Female; M – Male; BLT – bilateral lung transplantation; SLT – single lung transplantation; IPF – interstitial pulmonary fibrosis; COPD – chronic obstructive pulmonary disease; CPFE – combined pulmonary fibrosis and emphysema; PAH – pulmonary artery hypertension; PF – pulmonary fibrosis; CF – cystic fibrosis; IPH – idiopathic pulmonary hypertension; PAH – pulmonary artery hypertension; AAD – a1-antitrypsin deficiency; RLTx – re-transplantation; ILD – interstitial lung disease; OB – obliterative bronchiolitis; NCFB – non-CF bronchiectasis; HSP – hypersensitivity pneumonitis; NA – not available; SD – standard deviation.